Table 1 Distribution of 298 NHL cases and 889 control subjects according to matching variables (Swiss HIV Cohort Study, 1984–2004)
From: Hepatitis C virus and non-Hodgkin's lymphoma: findings from the Swiss HIV Cohort Study
NHL cases | Control subjects | |||
|---|---|---|---|---|
N | (%) | N | (%) | |
Centre | ||||
Basel | 28 | (9.4) | 84 | (9.5) |
Bern | 23 | (7.7) | 68 | (7.7) |
Geneva | 42 | (14.1) | 125 | (14.1) |
St Gallen | 9 | (3.0) | 27 | (3.0) |
Ticino | 8 | (2.7) | 24 | (2.7) |
Vaud | 57 | (19.1) | 169 | (19.0) |
Zurich | 131 | (44.0) | 392 | (44.1) |
Gender | ||||
Male | 246 | (82.6) | 733 | (82.5) |
Female | 52 | (17.5) | 156 | (17.6) |
Age at enrolment (years) | ||||
<30 | 83 | (27.9) | 249 | (28.0) |
30–44 | 141 | (47.3) | 425 | (47.8) |
⩾45 | 74 | (24.8) | 215 | (24.2) |
CD4+ at enrolment (cells μl−1) | ||||
<100 | 71 | (23.8) | 209 | (23.5) |
100–199 | 47 | (15.8) | 142 | (16.0) |
200–499 | 120 | (40.3) | 357 | (40.2) |
⩾500 | 60 | (20.1) | 181 | (20.4) |
Duration of follow-up (months) | ||||
<24 | 100 | (33.6) | 297 | (33.4) |
24–59 | 107 | (35.9) | 320 | (36.0) |
⩾60 | 91 | (30.5) | 272 | (30.6) |
